Eikon Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
EIKN$5.87-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $142,613 | $104,901 |
| Marketable securities | 388,565 | 231,074 |
| Prepaid expenses and other current assets | 15,400 | 12,542 |
| Restricted cash, current | 400 | 400 |
| Total current assets | 546,978 | 348,917 |
| Property and equipment, net | 133,071 | 142,898 |
| Operating lease right-of-use assets, net | 91,137 | 90,965 |
| Restricted cash, non-current | 7,845 | 7,771 |
| Other non-current assets | 539 | 4,183 |
| Total assets | $779,570 | $594,734 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $6,564 | $681 |
| Accrued expenses and other current liabilities | 39,287 | 44,298 |
| Operating lease liability, current | 9,445 | 10,028 |
| Total current liabilities | 55,296 | 55,007 |
| Operating lease liability, non-current | 242,774 | 247,291 |
| Other non-current liabilities | 15,000 | 10,000 |
| Total liabilities | 313,070 | 312,298 |
| Commitments and contingencies (see Note 7) | ||
| Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of June 30, 2026 and 262,597,889 shares authorized, 222,658,133 shares issued and outstanding, and aggregate liquidation preference of $1,159,762 as of December 31, 2025 | — | 1,161,470 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value; 50,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and no shares authorized, issued and outstanding as of December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized and 54,148,887 shares issued and outstanding as of June 30, 2026 and 340,650,000 shares authorized and 3,068,490 shares issued and outstanding as of December 31, 2025 | 5 | — |
| Additional paid-in capital | 1,558,371 | 41,475 |
| Accumulated deficit | (1,091,876) | (920,509) |
| Total stockholders’ equity (deficit) | 466,500 | (879,034) |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $779,570 | $594,734 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.